Figure 2 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

Key Points

• Significant tumor fraction changes correlated with improved clinical outcomes in patients treated with immune checkpoint inhibitors.
• Kaplan–Meier analysis showed a strong association between tumor fraction decrease and better rwPFS, with P-values highlight its significance.
• Observational analysis using a real-world dataset identifies candidate thresholds for tumor fraction changes indicating treatment response.
• These findings support potential biomarker development for personalized immunotherapy approaches in cancer management.